AT7519

• Description :

  AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

• Product Name Alternative :

  AT7519M

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Apoptosis; CDK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/at7519.html

• Purity :

  99.69

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl

• Molecular Formula :

  C16H17Cl2N5O2

• Molecular Weight :

  382.24

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29 (16) :2325-36.|[2]Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.|[3]Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9 (4) :920-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

• Citation 01 :

  Adv Sci (Weinh) . 2024 Mar;11 (11) :e2305260.|bioRxiv. 2024 September 07.|bioRxiv. 2025 Nov 17.|Dev Biol. 2024 Apr:508:93-106.|EMBO Mol Med. 2025 Nov 26.|Exp Eye Res. 2023 Feb:227:109391.|FASEB J. 2024 Apr 30;38 (8) :e23628.|Glycobiology. 2022 Aug 18;32 (9) :751-759.|Harvard Medical School LINCS LIBRARY|Oncogene. 2023 Nov;42 (47) :3503-3513.|PLoS One. 2025 Jun 17;20 (6) :e0324443.|RNA Biol. 2021 Nov 12;18 (sup2) :722-729.|Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Harvard Medical School LINCS LIBRARY

• CAS Number :

  [844442-38-2]